Shots:
- The US FDA has granted 510(k) clearance to the Hemastyl gel device to support chronic wound healing
- The Hemastyl gel is a topical formulation that enhances the tissue-repair environment to support wound closure, while the Periwound NerveStim device works with Hemastyl to restore periwound function
- The Periwound NerveStim device is in final FDA approval stages, with Rapid Nexus finalizing its Breakthrough Device Designation submission, expected in 30–45 days to expand use, speed reimbursement, & improve patient access
Ref: PRNewsWire | Image: Rapid Nexus | Press Release
Related News:- Thermo Fisher Scientific’s EXENT System Receives the US FDA’s 510(k) Clearance to Aid Multiple Myeloma Diagnosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
